Cargando…

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients

OBJECTIVES: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). METHODS: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichholiya, Meenu, Yadav, Arvind Kumar, Luhadia, S. K., Tahashildar, Jameela, Aseri, M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051245/
https://www.ncbi.nlm.nih.gov/pubmed/27721537
http://dx.doi.org/10.4103/0253-7613.190729
_version_ 1782458046742528000
author Pichholiya, Meenu
Yadav, Arvind Kumar
Luhadia, S. K.
Tahashildar, Jameela
Aseri, M. L.
author_facet Pichholiya, Meenu
Yadav, Arvind Kumar
Luhadia, S. K.
Tahashildar, Jameela
Aseri, M. L.
author_sort Pichholiya, Meenu
collection PubMed
description OBJECTIVES: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). METHODS: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-positive tubercular patients aged between 18 and 65 years of either sex. Serum uric acid level was monitored at 0(th), 2(nd), 4(th), 6(th), and 8(th) week of ATT. Patients whose uric acid level was found to be increased at 2(nd) week were finally recruited in the study. Ninety patients who developed hyperuricemia due to ATT were divided randomly into three groups (Group A - febuxostat, Group B - allopurinol, and Group C - control) of thirty patients each. Mean serum uric acid levels were calculated at all the weeks in all the groups, and serum uric acid levels were compared by applying student's t-test and ANOVA. RESULTS: Mean serum uric acid level decreased from 10.698 mg/dl (at 2(nd) week) to 7.846 mg/dl (at 8(th) week) in Group A and from 11.34 mg/dl (at 2(nd) week) to 7.280 mg/dl (at 8(th) week) in Group B. Numbers of adverse events encountered across both the treatment groups were same with both the drugs. CONCLUSION: Allopurinol and febuxostat were equally efficacious in lowering PZA induced raised serum uric acid level in tubercular patients, and it was possible to continue ATT without withdrawing PZA.
format Online
Article
Text
id pubmed-5051245
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-50512452016-10-07 A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients Pichholiya, Meenu Yadav, Arvind Kumar Luhadia, S. K. Tahashildar, Jameela Aseri, M. L. Indian J Pharmacol Research Article OBJECTIVES: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). METHODS: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-positive tubercular patients aged between 18 and 65 years of either sex. Serum uric acid level was monitored at 0(th), 2(nd), 4(th), 6(th), and 8(th) week of ATT. Patients whose uric acid level was found to be increased at 2(nd) week were finally recruited in the study. Ninety patients who developed hyperuricemia due to ATT were divided randomly into three groups (Group A - febuxostat, Group B - allopurinol, and Group C - control) of thirty patients each. Mean serum uric acid levels were calculated at all the weeks in all the groups, and serum uric acid levels were compared by applying student's t-test and ANOVA. RESULTS: Mean serum uric acid level decreased from 10.698 mg/dl (at 2(nd) week) to 7.846 mg/dl (at 8(th) week) in Group A and from 11.34 mg/dl (at 2(nd) week) to 7.280 mg/dl (at 8(th) week) in Group B. Numbers of adverse events encountered across both the treatment groups were same with both the drugs. CONCLUSION: Allopurinol and febuxostat were equally efficacious in lowering PZA induced raised serum uric acid level in tubercular patients, and it was possible to continue ATT without withdrawing PZA. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5051245/ /pubmed/27721537 http://dx.doi.org/10.4103/0253-7613.190729 Text en Copyright: © 2016 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Research Article
Pichholiya, Meenu
Yadav, Arvind Kumar
Luhadia, S. K.
Tahashildar, Jameela
Aseri, M. L.
A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
title A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
title_full A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
title_fullStr A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
title_full_unstemmed A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
title_short A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
title_sort comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051245/
https://www.ncbi.nlm.nih.gov/pubmed/27721537
http://dx.doi.org/10.4103/0253-7613.190729
work_keys_str_mv AT pichholiyameenu acomparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT yadavarvindkumar acomparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT luhadiask acomparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT tahashildarjameela acomparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT aseriml acomparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT pichholiyameenu comparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT yadavarvindkumar comparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT luhadiask comparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT tahashildarjameela comparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients
AT aseriml comparativestudyofefficacyandsafetyoffebuxostatandallopurinolinpyrazinamideinducedhyperuricemictubercularpatients